Cargando…
Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals
To date nearly all clinical trials of Alzheimer’s disease (AD) therapies have failed. These failures are, at least in part, attributable to poor endpoint choice and to inadequate recruitment criteria. Recently, focus has shifted to targeting at-risk populations in the preclinical stages of AD thus i...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522521/ https://www.ncbi.nlm.nih.gov/pubmed/31097733 http://dx.doi.org/10.1038/s41598-019-42632-w |